For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars
Moderna has been saying for years that it would diversify its portfolio beyond infectious diseases. Investors were waiting for late-stage proof. On Wednesday, they got it. Moderna's shares soared to multiyear highs after disclosing
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.